Results 81 to 90 of about 30,146 (272)

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review

Frontiers in Oncology
Myelofibrosis (MF) is a philadelphia chromosome-negative chronic myeloprolifera- tive neoplasm.It has a worse prognosis than polycythemia vera and essential thrombocy- themia.At present,both Chinese and foreign guidelines recommend ruxolitinib as first ...
Xiaohong Liu, Xiujuan Zhang, Hongxia Shi
doaj   +1 more source

Clinical Images: Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome presenting as aseptic pustular dermatosis: A rare clinical manifestation

Arthritis &Rheumatology, EarlyView.
Peter Chen, Héloïse Briançon, Deborah Eshagh, Tali‐Anne Szwebel, Benjamin Terrier, Pierre Sohier, Rudy Birsen   +6 more
wiley   +1 more source

Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

JEADV Clinical Practice, EarlyView.
This post hoc analysis examined the efficacy of ritlecitinib in subgroups of patients with vitiligo, defined by demographic and clinical characteristics. Patients completed the dose‐ranging and extension periods of the phase 2b study (NCT03715829) of ritlecitinib.
A. G. Pandya, I. Hamzavi, P. Ghosh, K. Ezzedine, J. E. Harris, R. Adiri, S. Chen, E. Peeva, Y. Yamaguchi   +8 more
wiley   +1 more source

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms [PDF]

, 2014
The transforming JAK2V617F kinase is frequently associated with myeloproliferative neoplasms (MPNs) and thought to be instrumental for the overproduction of myeloid lineage cells.
Chowdary, Tirumala K., Deshpande, Anagha, Griffin, James D., Ray, Arghya, Reddy, Mamatha M., Sattler, Martin, Schade, Georg O.M.   +6 more
core   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. [PDF]

Adv Sci (Weinh)
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Mei H, Wen W, Zhang W, Zhang S, Sun T, Li G, Zhang J, Qi S, Zhou J, Li B, Zhao Y, Chen X, Li B, Xue Y, Lu W, Sun Y, Wang J, Shan H, Zhang S, Huang Y, Chen Y, Wang W, Liu Q, Lu W, Tan L, Ding Y, Fu J, Long J, Zhang L, Zhao B, Liang A, Jiang B, Yang J.   +32 more
europepmc   +2 more sources

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Integrated multi‐omics analysis reveals metabolic reprogramming as a key driver of angiotensin II‐induced vascular remodeling

VIEW, EarlyView.
This study investigates the molecular alterations underlying angiotensin II (Ang II)‐induced vascular remodeling in cardiovascular diseases using a multi‐omics approach. Through data exploration and integrated multi‐omics analysis, our findings reveal that Ang II‐driven vascular injury in vascular smooth muscle cells is mediated by metabolic ...
Yiwei Hu, Dan Zhao, Lingyan Zhong, Jianxujie Zheng, Dongxue Zhang, Enhui Wu, Qian Shi, Liang Qiao, Ling Lin   +8 more
wiley   +1 more source

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era

Haematologica
The recent progress with ruxolitinib treatment might improve quality-of-life as well as overall survival in patients with primary myelofibrosis (PMF).
Yosuke Okada, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Kazuki Yoshimura, Masaharu Tamaki, Akari Matsuoka, Takuto Ishikawa, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Machiko Kusuda, Aki Tanihara, Shun-ichi Kimura, Shinichi Kako, Yoshinobu Kanda   +18 more
doaj   +1 more source

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis

, 2023
Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Rock Y. Y. Leung, Elaine Lee, Hugh Young Rienhoff, Yok‐Lam Kwong   +11 more
openalex   +2 more sources